ArticleCancer medicine2025
Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Oncotype DX Breast Recurrence Score test was designed for HR+, HER2- early breast cancer (eBC) to assist in the decision-making process for de-escalating adjuvant chemotherapy (CT). Its validity and utility have been demonstrated prospectively across multiple studies, though data on older patients remain limited.
methodsThis prospective cohort study included patients over 70 years with eBC treated between 2018 and 2023 at Tenon Hospital, Paris, France. Characteristics of populations eligible for the test and those with RS ≤ or > 25 were collected, along with oncogeriatric assessment and treatments; statistical analysis was performed for IDFS and OS.
resultsOf the 365 patients > 70 years, mean age was 77.6 years (range 70-96), with 84.4% diagnosed with HR+/HER2- eBC. Oncotype DX testing was performed in 85 patients (27.9% of HR+/HER2- eBC), revealing a Recurrence Score (RS) result > 25 in 14 patients (15%). The RS > 25 group had more grade 3 tumors, more pT2 tumors, and a higher Ki67 > 20%. In the RS > 25 group, 9 patients (64%) had oncogeriatric consultations, and 7 (50%) started the recommended adjuvant CT. Four patients received taxane-cyclophosphamide (TC) and 3 adriamycin-cyclophosphamide-taxane (AC-T), with 2 discontinuing due to taxane-induced neuropathy. Median IDFS was significantly lower in the RS > 25 group (p = 0.0023), with 4 of 5 recurrences occurring in patients who did not receive adjuvant CT. OS showed no significant difference by RS group (p = 0.87).
conclusionThis observational study highlights that the Oncotype DX test supports therapeutic de-escalation in patients with RS ≤ 25 and serves as a prognostic marker. Oncogeriatric evaluations are essential to guide adjuvant treatments in older breast cancer patients prior to using genomic signatures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.